{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T22:33:30Z","timestamp":1773354810820,"version":"3.50.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> To compare the therapeutic efficacies of high dose dexamethasone, prednisone and rituximab in combination with dexamethasone for newly diagnosed ITP (Immune Thrombocytopenia, ITP) patients.<\/jats:p><jats:p><jats:bold>Methods and results:<\/jats:bold> Relevant publications for this study were obtained by searching PubMed, Embase, Cochrane, and CNKI (National Knowledge Infrastructure, CNKI) databases following the PRISMA guidelines. A total of, 15 publications were retrieved that contained sufficient data from 1,362 patients for high quality analysis of this study endpoints. Data analysis was carried out using Stata 11.0 software.<\/jats:p><jats:p>The primary outcomes were OR (Overall Response, OR) at 1 month after intervention and SR at 6 and 12 months. The secondary outcomes were AEs and relapse. There were no differences in the OR, while the SR was higher at 6 months (<jats:italic>p<\/jats:italic> = 0.001) as well as 12 months (<jats:italic>p<\/jats:italic> &amp;lt; 0.001) in the rituximab + dexamethasone group. In addition, the incidences of AEs (<jats:italic>p<\/jats:italic> = 0.008) were also higher in the rituximab + dexamethasone group. Dexamethasone was superior to prednisone based on OR (<jats:italic>p<\/jats:italic> = 0.006). We found no differences in SR at 6 months between dexamethasone and prednisone but SR at 12 months was higher in the dexamethasone group (<jats:italic>p<\/jats:italic> = 0.014). The relapse rate was higher in the high dose dexamethasone group compared to the rituximab + dexamethasone group (<jats:italic>p<\/jats:italic> = 0.042).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> This demonstrated that new treatment options such as Rituximab + dexamethasone, could be a good alternative to traditional therapy in improving long-term response and reducing the rate of relapse. However, further studies are required on the increased risk of AEs associated with Rituximab + dexamethasone.<\/jats:p>","DOI":"10.3389\/fmed.2021.656792","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T04:22:16Z","timestamp":1621916536000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["The Efficacy of High-Dose Dexamethasone vs. Other Treatments for Newly Diagnosed Immune Thrombocytopenia: A Meta-Analysis"],"prefix":"10.3389","volume":"8","author":[{"given":"Qirong","family":"Xiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bicun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwu","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1056\/NEJMct1014202","article-title":"Thrombopoietin-receptor agonists for primary immune thrombocytopenia","volume":"365","author":"Imbach","year":"2011","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/jcm6020016","article-title":"Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)","volume":"6","author":"Zufferey","year":"2017","journal-title":"J Clin Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1016\/S2352-3026(15)00003-4","article-title":"Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis","volume":"2","author":"Chugh","year":"2015","journal-title":"Lancet Haematol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune thrombocytopenia","volume":"381","author":"Cooper","year":"2019","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/ejh.13319","article-title":"Autoimmune thrombocytopenia: current treatment options in adults with a focus on novel drugs","volume":"102","author":"Witkowski","year":"2019","journal-title":"Eur J Haematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2352-3026(16)30109-0","article-title":"High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis","volume":"3","author":"Mithoowani","year":"2016","journal-title":"Lancet Haematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1316096","DOI":"10.1155\/2018\/1316096","article-title":"Efficacy and safety of the combination treatment of rituximab and dexamethasone for adults with primary immune thrombocytopenia (ITP): a meta-analysis","volume":"2018","author":"Wang","year":"2018","journal-title":"Biomed Res Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.jclinepi.2013.03.003","article-title":"Testing the Newcastle Ottawa scale showed low reliability between individual reviewers","volume":"66","author":"Hartling","year":"2013","journal-title":"J Clin Epidemiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1182\/blood-2015-03-631937","article-title":"A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4)","volume":"126","author":"Choi","year":"2015","journal-title":"Blood."},{"key":"B10","article-title":"Combination therapy with recombinant human thrombopoietin and low-dose rituximab for corticosteroid-resistant\/relapsed adult ITP: a multicenter clinical trial","author":"Liu","year":"2015","journal-title":"J Clin Hematol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000362529","article-title":"Long-term effect of high-dose dexamethasone with or without low-dose dexamethasone maintenance in untreated immune thrombocytopenia","volume":"133","author":"Din","year":"2015","journal-title":"Acta Haematol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1159\/000445420","article-title":"A randomized trial of daily prednisone versus pulsed dexamethasone in treatment-naive adult patients with immune thrombocytopenia: EIS 2002 study","volume":"136","author":"Matschke","year":"2016","journal-title":"Acta Haematol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/j.1538-7836.2009.03359.x","article-title":"Faster platelet recovery by high-dose dexamethasone compared with standard-dose prednisolone in adult immune thrombocytopenia: a prospective randomized trial","volume":"7","author":"Praituan","year":"2009","journal-title":"J Thromb. Haemost."},{"key":"B14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2008-2231-20-7","article-title":"Single course of high dose dexamethasone is more effective than conventional prednisolone therapy in the treatment of primary newly diagnosed immune thrombocytopenia","volume":"20","author":"Mashhadi","year":"2012","journal-title":"Daru"},{"key":"B15","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s11239-013-0939-3","article-title":"Prednisone versus high-dose dexamethasone for untreated primary immune thrombocytopenia. A retrospective study of the Japan Hematology & Oncology Clinical Study Group","volume":"37","author":"Sakamoto","year":"2014","journal-title":"J Thromb Thrombolysis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2015-07-659656","article-title":"High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial","volume":"127","author":"Wei","year":"2016","journal-title":"Blood."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1182\/blood.V116.21.3687.3687","article-title":"High dose dexamethasone vs. conventional dose prednisolone for adults with immune thrombocytopenia: a prospective multicenter phase III trial","volume":"116","author":"Ryoo","year":"2010","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3760\/cma.j.issn.0578-1426.2011.05.011","article-title":"[The efficacy and safety of 2 cycles' high-dose dexamethasone treatment adult primary immune thrombocytopenia]","volume":"50","author":"Cui","year":"2011","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"B19","first-page":"478","article-title":"[Effect of different therapeutic regimens on regulatory T cells in patients of primary immune thrombocytopenia]","volume":"34","author":"Li","year":"2013","journal-title":"Zhonghua Xue Ye Xue Za Zhi."},{"key":"B20","first-page":"633","article-title":"High dose dexamethasone vs prednisolone therapy in newly diagnosed Myanmar adult patients with primary immune thrombocytopenia","volume":"3","author":"Nyein","year":"2019","journal-title":"Res Pract Thrombosis Haemostasis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/ejh.12102","article-title":"High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia","volume":"90","author":"Gomez-Almaguer","year":"2013","journal-title":"Eur J Haematol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1182\/blood-2012-09-455691","article-title":"Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia","volume":"121","author":"Gudbrandsdottir","year":"2013","journal-title":"Blood."},{"key":"B23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12185-010-0753-z","article-title":"Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia","volume":"93","author":"Li","year":"2011","journal-title":"Int J Hematol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1182\/blood-2009-07-229815","article-title":"Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia","volume":"115","author":"Zaja","year":"2010","journal-title":"Blood"},{"key":"B25","article-title":"Effect of Large dose of dexamethasone combined with rituximab on CD4~+CD25~+ treg cells in patients with primary immune thrombocytopenia","author":"Cui","year":"2015","journal-title":"Chin J N Clin Med."},{"key":"B26","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","year":"2017"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1182\/blood-2008-04-150078","article-title":"Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP","volume":"113","author":"Bussel","year":"2009","journal-title":"Blood."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American society of hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv."},{"key":"B29","doi-asserted-by":"publisher","first-page":"4765","DOI":"10.3390\/ijms20194765","article-title":"Corticosteroids in acute lung injury: the dilemma continues","volume":"20","author":"Mokra","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3324\/haematol.2017.174615","article-title":"Comparison of up-front treatments for newly diagnosed immune thrombocytopenia -a systematic review and network meta-analysis","volume":"103","author":"Arai","year":"2018","journal-title":"Haematologica."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.656792\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T04:22:24Z","timestamp":1621916544000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.656792\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":30,"alternative-id":["10.3389\/fmed.2021.656792"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.656792","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,25]]},"article-number":"656792"}}